A Case of Severe Pneumocystis Pneumonia in an HIV-Negative Patient Successfully Treated with Oral Atovaquone
Jun Hirai,Nobuaki Mori,Hideo Kato,Nobuhiro Asai,Mao Hagihara,Hiroshige Mikamo
DOI: https://doi.org/10.2147/IDR.S406904
2023-03-18
Infection and Drug Resistance
Abstract:Jun Hirai, 1, 2 Nobuaki Mori, 1, 2 Hideo Kato, 3 Nobuhiro Asai, 1, 2 Mao Hagihara, 4 Hiroshige Mikamo 1, 2 1 Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Nagakute, Aichi, Japan; 2 Department of Infection Control and Prevention, Aichi Medical University Hospital, Nagakute, Aichi, Japan; 3 Department of Pharmacy, Mie University Hospital, Mie, Japan; 4 Department of Molecular Epidemiology and Biomedical Sciences, Aichi Medical University, Nagakute, Aichi, Japan Correspondence: Jun Hirai, Department of Clinical Infectious Diseases, Aichi Medical University Hospital, 1-1, Yazako-karimata, Nagakute, Aichi, 480-1195, Japan, Tel +81-561-62-3311, Fax +81-561-76-2673, Email Currently, atovaquone is not recommended for treating severe Pneumocystis jirovecii pneumonia (PCP) due to insufficient evidence in clinical studies. This report describes a case of severe PCP in a human immunodeficiency virus (HIV)-negative immunosuppressed patient who was successfully treated with oral atovaquone and corticosteroids. A 63-year-old Japanese woman complained of fever and dyspnea for 3 days. She had been treated with oral prednisolone (30 mg/day) for interstitial pneumonia for 3 months without PCP prophylaxis. Although we could not confirm P. jirovecii from the respiratory specimen, a diagnosis of PCP was indicated by marked elevation of serum beta-D-glucan levels and bilateral ground-glass opacities in the lung fields. Based on the arterial blood gas test results (alveolar-arterial oxygen difference > 45 mmHg), the disease status of PCP was defined as severe. Trimethoprim-sulfamethoxazole (SXT) is the first-line drug for treating severe PCP. However, given the patient's history of SXT-induced toxic epidermal necrolysis, she was administered atovaquone instead of SXT. Her clinical symptoms and respiratory condition gradually improved, with a 3-week treatment showing a good clinical course. Previous clinical studies on atovaquone have only been conducted in HIV-positive patients with mild or moderate PCP. Accordingly, the clinical efficacy of atovaquone for severe PCP cases or PCP in HIV-negative patients remains unclear. There is a rising incidence of PCP among HIV-negative patients, given the increasing number of patients receiving immunosuppressive medications; moreover, atovaquone has less severe side effects than SXT. Therefore, there is a need for further clinical investigation to confirm the efficacy of atovaquone in cases of severe PCP, especially among HIV-negative patients. In addition, it also remains unclear whether corticosteroids are beneficial for severe PCP in non-HIV patients. Thus, the use of corticosteroids in cases of severe PCP in non-HIV patients should also be investigated. Keywords: Pneumocystis pneumonia, severe, atovaquone, trimethoprim-sulfamethoxazole, corticosteroid Pneumocystis jirovecii pneumonia (PCP), first described as a human pathogen in 1942 by van der Meer and Brug, 1 is a potentially life-threatening pulmonary infectious disease that generally occurs in immunocompromised individuals. 2 In individuals with human immunodeficiency virus (HIV) infection, the PCP incidence decreased from 29.9 per 1000 person-years during 1994 to 1997 to 3.9 per 1000 person-years during 2003 to 2007, 3 whereas approximately 5–15% of HIV-negative immunocompromised individuals developed PCP in the absence of prophylaxis. 4–7 Established risk factors for PCP include HIV infection, chemotherapy treatment for a malignant disease, and reception of hematopoietic cells or solid organ transplants. 8 The incidence of PCP among patients with HIV has dramatically decreased after the introduction of antiretroviral therapy and PCP prophylaxis with trimethoprim-sulfamethoxazole (SXT). However, there is an increasing incidence of PCP among HIV-negative patients receiving immunosuppressive medications, including corticosteroids and biological products, such as tumor necrosis factor-α inhibitors and methotrexate. 9,10 There remain no initiation criteria for PCP prophylaxis among HIV-negative patients receiving immunosuppressive agents. Currently, 21-day treatment with SXT is the most common therapeutic strategy for PCP in both HIV-infected and HIV-negative patients; 11,12 however, some patients cannot tolerate this treatment due to severe allergies, including Stevens–Johnson syndrome and toxic epidermal necrolysis (TEN). Atovaquone is an alternative drug for PCP treatment and is better tolerated than SXT; however, it is currently not recommended for severe PCP due to insufficient evidence. 13 This report describes a case of severe PCP in a -Abstract Truncated-
pharmacology & pharmacy,infectious diseases